Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms
NCT ID: NCT07337967
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
120 participants
OBSERVATIONAL
2026-01-01
2027-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Young Patients With Acute Myeloid Leukemia
NCT01138332
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia
NCT01057290
Study of the Immunological Infiltrate and Immunometabolic Immunometabolic Profile of Patients with Acute Leukaemia
NCT06814444
Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
NCT01298414
Immunophenotyping of Acute b Cell Lymphoblstic Leukemia
NCT04084327
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1. Patients with Active bleeding
2. Patients with recent blood transfusion (less than 2 weeks).
3. Patients on haematinics or vitamin B 12 therapy
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Huda Ahmed Abdelsabour Abdelwahab
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Huda Ahmed Abdelsabour Abdelwahab
Resident doctor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUN-FOM-CP-CLPD-RETIC-2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.